Description
BAYER / CARDINAL RA-223 XOFIGO RX INJECTIONS
First action · last action
2019-11-01 · 2019-11-01
Transactions
3
First transaction's obligation
$356,355
Base + all options value (sum of deltas)
$292,836
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P2202D
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2019-11-01+$356,355= $356,355
- Mod P000012019-11-01+$0= $356,355
- Mod P000022019-11-01-$63,519= $292,836
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2019-11-01 | +$356,355 | $356,355 | BAYER / CARDINAL RA-223 XOFIGO RX INJECTIONS |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2019-11-01 | +$0 | $356,355 | BAYER / CARDINAL RA-223 XOFIGO RX INJECTIONS |
| Mod P00002· OTHER ADMINISTRATIVE ACTION | 2019-11-01 | −$63,519 | $292,836 | BAYER / CARDINAL RA-223 XOFIGO RX INJECTIONS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V1EVGCK7XES8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25626N0492 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $386,860 | FY2026 |
| 36C26226F0163 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $181,386 | FY2026 |
| 36C26026F0086 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $80,663 | FY2026 |
| 36C26126N0199 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $101,567 | FY2026 |
| 36C25626N0126 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6505 · DRUGS AND BIOLOGICALS | $214,783 | FY2026 |
| 36E79725A0028 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2025 |
Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26026F0379 | COSETTE PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $3,466 | FY2026 |
| 36C26026P0671 | MCKESSON PLASMA AND BIOLOGICS LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $18,262 | FY2026 |
| 36C26026F0349 | AGIOS PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $73,080 | FY2026 |
| 36C26026F0306 | BRACCO DIAGNOSTICS INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $337,422 | FY2026 |
| 36C26026F0298 | PROGENICS PHARMACEUTICALS INC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $469,134 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26020N0156_3600_V797P2202D_3600 · retrieved 2026-09-26.